Abstract
Colorectal Cancer (CRC) is a leading cause of cancer deaths in the United States. Despite significant overall declines in CRC incidence and mortality, there has been an alarming increase in CRC among people younger than 50. This study uses an established microsimulation model, CRC-SPIN, to perform a ‘stress test’ of colonoscopy screening strategies. First, we expand CRC-SPIN to include birth-cohort effects. Second, we estimate natural history model parameters via Incremental Mixture Approximate Bayesian Computation (IMABC) for two model versions to characterize uncertainty while accounting for increased early CRC onset. Third, we simulate 26 colonoscopy screening strategies across the posterior distribution of estimated model parameters, assuming four different colonoscopy sensitivities (104 total scenarios). We find that model projections of screening benefit are highly dependent on natural history and test sensitivity assumptions, but in this stress test, the policy recommendations are robust to the uncertainties considered.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by a Rothenberg Dissertation Award provided by the Pardee RAND Graduate School and by the National Cancer Institute (NCI) as part of the Cancer Intervention and Surveillance Modeling Network (CISNET) through grant U01-CA253913. This research used resources of the Argonne Leadership Computing Facility, a DOE Office of Science User Facility supported under Contract DE-AC02-06CH11357. I thank the Argonne Leadership Computing Facility staff for their timely and critical support. This research was completed with resources provided by the Laboratory Computing Resource Center at Argonne National Laboratory.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.